8-K: Rafael Holdings Reports Third Quarter Fiscal 2024 Results, Net Loss Driven by R&D Expenses

Rafael Holdings reported a significant net loss for the third quarter of fiscal 2024, primarily due to a large in-process research and development expense, while highlighting progress in its portfolio companies.

Summary

• Rafael Holdings reported its financial results for the third quarter of fiscal year 2024, ending April 30, 2024.
• The company had $72.4 million in cash, cash equivalents, and marketable securities as of April 30, 2024.
• A net loss from continuing operations of $32.4 million, or $1.36 per diluted share, was recorded for the quarter, compared to a $1.4 million loss, or $0.06 per diluted share, in the same period last year.
• The net loss was primarily driven by an $89.9 million in-process research and development expense.
• This was partially offset by a $31.3 million recovery of receivables from Cornerstone due to an additional investment, which was treated as an acquisition for accounting purposes.
• The company increased its investment in Day Three Labs to a 79% majority interest and began consolidating its financial results in January 2024.
• An unrealized loss of $4.4 million was recognized on the investment in Cyclo Therapeutics.
• Research and development expenses increased to $1.5 million from $0.7 million year-over-year due to new activity at Cornerstone and Day Three Labs.
• General and administrative expenses decreased to $1.9 million from $2.3 million year-over-year due to decreases in payroll and related expenses.
• For the first nine months of fiscal 2024, the net loss from continuing operations was $29.9 million, or $1.26 per diluted share, compared to a $9.6 million loss, or $0.42 per diluted share, in the prior year period.
• The nine-month loss was driven by the $89.9 million in-process R&D expense and a $1.6 million loss on the initial investment in Day Three Labs, offset by the $31.3 million recovery from Cornerstone and a $3.2 million unrealized gain on the Cyclo Therapeutics investment.
• Research and development expenses for the nine months decreased to $2.6 million from $5.0 million year-over-year due to the winding down of early-stage programs.
• General and administrative expenses for the nine months decreased to $6.5 million from $7.5 million year-over-year, primarily due to a decrease in non-cash stock-based compensation and payroll expenses.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the significant net loss and large R&D expenses, although there are some positive developments in portfolio companies. The overall financial results are worse than the previous year.

Positives

• Cyclo Therapeutics completed enrollment in its pivotal Phase 3 study for Trappsol Cyclo, a significant milestone.
• Day Three Labs has started generating revenue, indicating progress in their business model.
• The company recovered $31.3 million in receivables from Cornerstone due to an additional investment.
• General and administrative expenses decreased year-over-year, showing cost management efforts.
• The company has a substantial cash position of $72.4 million.

Negatives

• The company reported a significant net loss of $32.4 million for the third quarter of fiscal 2024.
• The net loss was primarily driven by a large $89.9 million in-process research and development expense.
• An unrealized loss of $4.4 million was recognized on the investment in Cyclo Therapeutics for the quarter.
• The company recorded a net loss of $29.9 million for the first nine months of fiscal 2024.
• Research and development expenses increased year-over-year for the quarter.

Risks

• The company's significant net losses, driven by R&D expenses, could impact future financial stability.
• The unrealized loss on the Cyclo Therapeutics investment indicates potential volatility in the value of their holdings.
• The company's reliance on strategic investments carries inherent risks associated with the performance of those investments.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company will continue to develop its existing portfolio and evaluate opportunities for strategic investment, focusing on therapeutics that address high unmet medical needs. The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Management Comments

• During fiscal 2024, we have continued to develop our existing portfolio while actively evaluating opportunities for strategic investment, said Bill Conkling, CEO of Rafael Holdings.
• We are particularly pleased that Cyclo Therapeutics (Nasdaq:CYTH) announced the completion of enrollment in its pivotal Phase 3 study evaluating Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease.
• We are also encouraged by the execution at Day Three Labs, as it began generating revenue by reimagining existing cannabis offerings with pharmaceutical-grade technology to bring to market better, cleaner, more precise, and predictable products.

Industry Context

The announcement reflects the ongoing challenges and opportunities in the biotechnology and pharmaceutical sectors, where significant R&D investments are often necessary but can lead to substantial losses in the short term. The company's focus on strategic investments and portfolio development is consistent with industry trends of diversification and innovation.

Comparison to Industry Standards

• The significant R&D expense of $89.9 million is substantial compared to other holding companies, but is not unusual for companies with a focus on early-stage pharmaceutical development.
• The net loss of $32.4 million for the quarter is significant, and would be considered worse than average for a holding company, but is not unusual for a company with a focus on early-stage pharmaceutical development.
• The completion of enrollment in Cyclo Therapeutics' Phase 3 study is a positive milestone, comparable to other clinical-stage biotech companies reaching similar stages.
• Day Three Labs' revenue generation is a positive sign, but its impact on the overall financials is still limited at this stage, similar to other early-stage cannabis companies.
• The company's cash position of $72.4 million is relatively strong, providing a buffer for ongoing operations and investments, which is comparable to other companies of similar size and stage.

Stakeholder Impact

• Shareholders may be concerned about the significant net loss, but encouraged by the progress in portfolio companies.
• Employees may be affected by the cost management efforts, including decreases in payroll expenses.
• Customers of Day Three Labs may benefit from the introduction of pharmaceutical-grade cannabis products.
• Suppliers and creditors may be impacted by the company's financial performance and investment decisions.

Next Steps

• The company will continue to develop its existing portfolio.
• The company will actively evaluate opportunities for strategic investment.
• The company will focus on therapeutics which address high unmet medical needs.

Key Dates

Keywords

Rafael Holdings, Financial Results, Net Loss, Research and Development, Cyclo Therapeutics, Day Three Labs, Investment, Pharmaceuticals, Cannabis, Cornerstone Pharmaceuticals